Skip to main content

Spero Therapeutics, Inc.

SPRO
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001701108

No open-market purchases or sales by Spero Therapeutics, Inc. insiders were filed in the last 90 days; 59 institutions reported holding it in 13F filings for Q2 2026, worth $47.5M in total; no superinvestor holds it.

Q4 2022 vs. Q3 2022

How the institutions holding Spero Therapeutics, Inc. changed between Q3 2022 and Q4 2022.

All holders in Q4 2022All holders in Q3 2022

13F holders of SPRO: Q3 2022 compared with Q4 2022
MeasureQ3 2022Q4 2022Change
Holders6960−9
Shares19.9M14.2M−5.63M (−28.4%)
Value$39.7M$24.6M−$15.1M (−38.1%)

New holders (14)

Institutions that held Spero Therapeutics, Inc. at the end of Q4 2022 but not at the end of Q3 2022.

Institutions new to SPRO in Q4 2022
InstitutionSharesValue% of portfolio
XTX Topco Ltd346,734$599.9K0.13%
Two Sigma Investments, LP39,795$68.8K0.00%
Virtu Financial LLC34,369$59.0K0.01%
Charles Schwab Investment Management Inc28,565$49.4K0.00%
Two Sigma Securities, LLC23,523$40.7K0.01%
CI Private Wealth, LLC17,500$30.3K0.00%
Prudential Financial Inc14,600$25.3K0.00%
Invesco Ltd.12,073$20.9K0.00%
Texas Yale Capital Corp.10,000$17.3K0.00%
Colony Group LLC10,000$17.0K0.00%
Belpointe Asset Management LLC4,560$7.89K0.00%
CoreCap Advisors, LLC142$2460.00%
GWM Advisors LLC100$00.00%
Steward Financial Group LLC354$00.00%

Sold out (23)

Institutions that held Spero Therapeutics, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.